- Home
- EAD vs CCCC Comparison
EAD vs CCCC Comparison
Compare EAD & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EAD | CCCC |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 356.3M | 350.6M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | EAD | CCCC |
|---|---|---|
| Price | $5.93 | $2.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $12.86 |
| AVG Volume (30 Days) | 304.4K | ★ 2.0M |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | ★ 8.91% | N/A |
| EPS Growth | N/A | ★ 16.45 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,947,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1.02 |
| 52 Week Low | $5.92 | $1.69 |
| 52 Week High | $6.97 | $5.17 |
Technical Indicators
Market Signals| Indicator | EAD | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 31.09 | 37.47 |
| Support Level | $5.92 | $2.52 |
| Resistance Level | $6.09 | $3.91 |
| Average True Range (ATR) | 0.08 | 0.21 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 8.34 | 14.64 |
Price Performance
Historical ComparisonAbout EAD Allspring Income Opportunities Fund
Allspring Income Opportunities Fund is a diversified closed-end management investment company. The Fund seeks a high level of current income. Capital appreciation is a secondary objective. The fund has single operating segment.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.